Literature DB >> 9543059

CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.

C Cesana1, C Carlo-Stella, E Regazzi, D Garau, G Sammarelli, C Caramatti, A Tabilio, L Mangoni, V Rizzoli.   

Abstract

Mobilized peripheral blood progenitor cells (PBPC) are increasingly used as an alternative to bone marrow for autografting procedures. Currently, cyclophosphamide (CY) followed by granulocyte colony-stimulating factor (G-CSF) or G-CSF alone are the most commonly used PBPC mobilization schedules. In an attempt to investigate whether the use of these two mobilization regimens could result in the collection of functionally different CD34+ cells, we analyzed nucleated cells (NC), CD34+ cells, committed progenitor cells and long-term culture initiating-cells (LTC-IC) in 52 leukaphereses from 26 patients with lymphoid malignancies, mobilized either by CY+G-CSF (n=16) or G-CSF alone (n=10). Thirty-four aphereses from the CY+G-CSF group and 18 aphereses from the G-CSF group were investigated. According to the study design, leukaphereses were carried out until an average number of 7 x 10(6) CD34+ cells/kg body weight were collected. The mean (+/-s.e.m.) numbers of CD34+ cells mobilized per apheresis by CY+G-CSF and G-CSF were not significantly different (2.76+/-0.6 x 10(8) vs 2.53+/-0.4 x 10(8), P < or = 0.7). This resulted from a mean number of NC that was significantly lower in the CY+G-CSF products than in the G-CSF products (12.4+/-1.7 x 10(9) vs 32+/-5.4 x 10(9), P < or = 0.0001) and a mean incidence of CD34+ cells that was significantly higher in the CY+G-CSF products than in the G-CSF products (2.9+/-0.6% vs 0.9+/-0.2%, P < or = 0.0018). The mean (+/-s.e.m.) number of CFU-GM collected per apheresis was significantly higher in the CY+G-CSF group than in the G-CSF group (37+/-7 x 10(6) vs 14+/-2 x 10(6), P < or = 0.03). Interestingly, CY+G-CSF-mobilized CD34+ cells had a significantly higher plating efficiency than G-CSF-mobilized CD34+ cells (25.5+/-2.9% vs 10.8+/-1.9%, P < or = 0.0006). In addition, the mean number of LTC-IC was significantly higher in the CY+G-CSF products than in the G-CSF products (6.3+/-1 x 10[6] vs 3.3+/-0.3 x 10[6], P < or = 0.05). In conclusion, our data provide evidence that CY+G-CSF and G-CSF induce the mobilization of CD34+ cells with different clonogenic potential. As mobilized PBPC containing large numbers of progenitors lead to safer transplantation, this issue may have implications for planning mobilization strategies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9543059     DOI: 10.1038/sj.bmt.1701133

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  4 in total

1.  Immune mobilization of autologous blood progenitor cells: direct influence on the cellular subsets collected.

Authors:  Kenneth R Meehan; Laleh Talebian; Jillian Wu; John M Hill; Zbigniew M Szczepiorkowski; Charles L Sentman; Marc S Ernstoff
Journal:  Cytotherapy       Date:  2010-09-27       Impact factor: 5.414

2.  Novel mobilization strategies to enhance autologous immune effector cells in multiple myeloma.

Authors:  Laleh Talebian; Jia Yan Wu; Dawn A Fischer; John M Hill; Zbigniew M Szczepiorkowski; Marc S Ernstoff; Charles L Sentman; Kenneth R Meehan
Journal:  Front Biosci (Elite Ed)       Date:  2011-06-01

Review 3.  The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.

Authors:  Der-Cherng Liang
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

4.  Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.

Authors:  Halvard Bonig; Annette Wundes; Kai-Hsin Chang; Sylvia Lucas; Thalia Papayannopoulou
Journal:  Blood       Date:  2008-01-14       Impact factor: 22.113

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.